Moxifloxacin, R207910 and linezolid

EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS

Moxifloxacin, R207910 and linezolid

---

TARGET PROTEIN

topoisomerase II (DNA gyrase) and topoisomerase IV

---

MECHANISM OF ACTION

Bactericidal activity

---

DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)

Experimental

---

MODE OF ADMINISTRATION

Oral

---

LINK TO PUBMED

https://pubmed.ncbi.nlm.nih.gov/16723546/

---

EXTERNAL LINKS

PubChem Compound 152946

---

REFERENCE

Ji, B., Lefrancois, S., Robert, J., Chauffour, A., Truffot, C., & Jarlier, V. (2006). In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrobial Agents and Chemotherapy, 50(6), 1921?1926. https://doi.org/10.1128/AAC.00052-06



Kim, H., Mori, S., Kenri, T., & Suzuki, Y. (2021). Molecular characterization of Mycobacterium ulcerans DNA gyrase and identification of mutations reduced susceptibility against quinolones in vitro. BioRxiv, 2021.09.29.462499. https://doi.org/10.1101/2021.09.29.462499



Organization, W. H. (2012). Treatment of Mycobacterium ulcerans disease (Buruli Ulcer): Guidance for health workers. | Infolep. https://www.leprosy-information.org/resource/treatment-mycobacterium-ulcerans-disease-buruli-ulcer-guidance-health-workers

---